Last reviewed · How we verify

Lutinus + transfer day 6

Anja Bisgaard Pinborg · FDA-approved active Small molecule

Lutinus is a progesterone supplement used to support luteal phase function and embryo implantation during assisted reproductive technology cycles.

Lutinus is a progesterone supplement used to support luteal phase function and embryo implantation during assisted reproductive technology cycles. Used for Luteal phase support in assisted reproductive technology (ART) cycles, Progesterone supplementation after embryo transfer on day 6.

At a glance

Generic nameLutinus + transfer day 6
Also known asLutinus
SponsorAnja Bisgaard Pinborg
Drug classProgesterone supplement
TargetProgesterone receptor
ModalitySmall molecule
Therapeutic areaReproductive Medicine / Fertility
PhaseFDA-approved

Mechanism of action

Lutinus (micronized progesterone) provides exogenous progesterone to supplement endogenous production during the luteal phase after ovulation or embryo transfer. Progesterone is essential for endometrial preparation and maintenance of early pregnancy by promoting secretory changes in the uterus and suppressing uterine contractions. The 'transfer day 6' designation indicates use as luteal phase support beginning 6 days after embryo transfer in in vitro fertilization (IVF) protocols.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: